Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation

Abstract

Jinlian Zhu,1 Jie Chen,1 Wei Liu,1 Junling Zhang,2 Yulan Gu1 1Department of Oncology, Affiliated Changshu Hospital of Nantong University, Changshu, Jiangsu Province, People’s Republic of China; 2Medical Department, 3D Medicines Inc, Shanghai, People’s Republic of ChinaCorrespondence: Yulan Gu, Email [email protected]: Mesenchymal-epithelial transition (MET) gene has been identified as a promising target for treatments. However, different sites of the MET mutation show different effects to MET inhibition. Here, we reported a non-small cell lung cancer (NSCLC) patient harboring MET Y1003H mutation who achieved a durable partial response to crizotinib with a PFS of 22.4 months. Furthermore, we report for the first time the identification of MET D1228N as a possible mechanism of acquired resistance to crizotinib in a patient with MET Y1003H mutation during disease progression.Keywords: MET Y1003H, MET D1228N, crizotinib, resistance, NSCLC

Keywords

• met y1003h
• met d1228n
• crizotinib
• resistance
• nsclc